Parker Waichman LLP

Hemlibra Death Lawsuit Lawyers

Parker Waichman LLP is Reviewing Hemlibra Fatality Claims Nationwide According to a news report by biocentury.com, pharmaceutical corporation Genentech Inc. has reported five deaths in patients taking its new hemophilia drug.*   In a statement released March 27, the Hemophilia Federation of America said it had been notified by Genentech, a unit of Roche, that […]

Parker Waichman LLP is Reviewing Hemlibra Fatality Claims Nationwide

According to a news report by biocentury.com, pharmaceutical corporation Genentech Inc. has reported five deaths in patients taking its new hemophilia drug.*

Hemlibra Fatality Claims

 

In a statement released March 27, the Hemophilia Federation of America said it had been notified by Genentech, a unit of Roche, that five people taking the drug Hemlibra had died. Hemlibra was approved by the U.S. Food and Drug Administration in November 2017 to treat adults and children with hemophilia A. It is a bispecific factor IXa- and factor X-directed antibody that can be injected to prevent bleeding episodes in patients with hemophilia A with factor VIII inhibitors.

Genentech indicated that one of the reported deaths occurred in 2017 during the Hemlibra clinical trial called Phase III HAVEN 1. This patient reportedly suffered a severe rectal hemorrhage, which led to the patient’s death. Genentech said in a statement that it had investigated the incident and concluded the patient’s death was not related to treatment with Hemlibra.

Little information has been shared by Roche or Genentech about the four additional patient deaths, other than that one occurred in 2016, one in 2017, and two in 2018. The lack of information is likely because all four of these patients were taking ‘Hemlibra’ under an expanded access program (also known as a “compassionate use” program). Expanded access means the drug was experimental at the time (not approved by the FDA), and the patient was taking it outside of a clinical trial. Though it has not shared causes of death for these patients, Genentech has maintained these four deaths were also not caused by Hemlibra.

In addition to the deaths recently reported by Genentech, Hemlibra is associated with other serious adverse events. As approved, the Hemlibra drug label contains a Black Box warning (the strongest warning for a drug label) about adverse events observed during clinical trials. Patients in clinical trials taking ‘Hemlibra’ with certain other medications — activated prothrombin complex concentrates (aPCCC) used to control or reverse a bleeding event — developed a condition called thrombotic microangiopathy. Thrombotic microangiopathy is a disease in which blood vessels in some of the body’s most vital organs, like the brain and kidneys, become damaged. The condition can be fatal.

In the case of the patient who died from a rectal hemorrhage, ‘Hemlibra’ adverse events overlapped. As explained in a statement from Roche to the European Hemophilia Association, this patient suffered a serious bleed while taking Hemlibra during a clinical trial and was given an activated prothrombin complex concentrate to reverse the bleed. The patient then developed thrombotic microangiopathy, and the aPCCC was withdrawn. The bleeding event could then not be controlled, and the patient died.

Genentech is headquartered in San Francisco and has been a subsidiary of Roche since 2009. It manufacturers numerous well-known prescription medications, including Boniva, Klonopin, and Tamiflu.

About Roche and the Hemlibra Drug

Roche is a multinational healthcare company headquartered in Basel, Switzerland. ‘Hemlibra’ represents an expansion into the hematology market for Roche, which is already known for several drugs used to treat blood cancers. Its oncology drugs Rituxan, Avastin, and Herceptin are near patent expiration, and it is thought Roche introduced Hemlibra to try to bridge the anticipated revenue gap created when those drugs lose patent protection.

Reuters reports that Hemlibra costs approximately $450,000 a year, and analysts believe the drug can soon hit $5 billion in annual sales. In light of news breaking about the five patient deaths, Roche’s shares dropped, according to a report by Reuters. Just as Roche was coming off a legal patent victory in Japan concerning ‘Hemlibra’, its shares dipped 2 percent by March 28.

Contact Parker Waichman LLP for Your Free Hemlibra Death Case Evaluation

If you or your family member has been taking a Hemlibra and unexpectedly passed away, contact our law firm today for your free consultation by filling out our online form or by calling 1-800-YOURLAWYER (1-800-968-7529).

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
ivan makoviychuk
4 years ago
5 Star Reviews 150
Positive: Professionalism , Quality , Responsiveness Benita, I am so grateful for your passion, professionalism and dedication. I appreciate the amazing legal work you did on my behalf. Thank you so much!
Amelia Hendricks
3 years ago
5 Star Reviews 150
Nicoleta Mereuta ,answers all my questions and she was polite. She was a pleasure to talk too.
Brenda Simmons
7 months ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038